These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 27745640)
21. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients. Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677 [TBL] [Abstract][Full Text] [Related]
22. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge. Ponti G; Manfredini M; Tomasi A; Pellacani G Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115 [TBL] [Abstract][Full Text] [Related]
23. Muir-Torre syndrome: Diagnostic and screening guidelines. Jones B; Oh C; Mangold E; Egan CA Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population. Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614 [TBL] [Abstract][Full Text] [Related]
25. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome. Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475 [TBL] [Abstract][Full Text] [Related]
26. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. Roberts ME; Riegert-Johnson DL; Thomas BC; Thomas CS; Heckman MG; Krishna M; DiCaudo DJ; Bridges AG; Hunt KS; Rumilla KM; Cappel MA J Genet Couns; 2013 Jun; 22(3):393-405. PubMed ID: 23212176 [TBL] [Abstract][Full Text] [Related]
27. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome. Ponti G; Manfredini M; Pellacani G; Tomasi A Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151 [TBL] [Abstract][Full Text] [Related]
28. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018. Cook S; Pethick J; Kibbi N; Hollestein L; Lavelle K; de Vere Hunt I; Turnbull C; Rous B; Husain A; Burn J; Lüchtenborg M; Santaniello F; McRonald F; Hardy S; Linos E; Venables Z; Rajan N J Am Acad Dermatol; 2023 Dec; 89(6):1129-1135. PubMed ID: 37031776 [TBL] [Abstract][Full Text] [Related]
29. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients. Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397 [TBL] [Abstract][Full Text] [Related]
32. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports. Cohen PR; Kurzrock R Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859 [TBL] [Abstract][Full Text] [Related]
35. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome. Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397 [TBL] [Abstract][Full Text] [Related]
36. [Case report: Muir-Torre syndrome diagnosed from a sebaceoma mimicking an ulcerated breast cancer]. Demolin G; Romain M; Münschke A; Vandingenen T; Blaude MA; Van Craynest MP J Gynecol Obstet Biol Reprod (Paris); 2016 Sep; 45(7):767-74. PubMed ID: 26321614 [TBL] [Abstract][Full Text] [Related]
37. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy? Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564 [TBL] [Abstract][Full Text] [Related]
39. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases. Boennelycke M; Thomsen BM; Holck S Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183 [TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations. Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]